Introduction
============

There is substantial evidence that increased release of the potent vasoconstrictor, endothelin (ET)-1, underlies the sustained elevated vascular tone in numerous pathophysiologies associated with endothelial dysfunction ([@B18]; [@B15]). In contrast, there is considerably less support for ET-1 in the regulation of vascular tone under physiologic conditions ([@B18]; [@B15]) although notable amongst this support is (1) endothelial ET~B~ receptor-mediated lowering of arterial pressure, due to nitric oxide (NO) release and ET-1 clearance ([@B16]; [@B19]; [@B25]; [@B3]; [@B23]), and (2) ET~A~ and ET~A/B~ receptor-mediated pressure elevation due to activation of these receptors on smooth muscle, albeit findings of lowered pressure in response to ET~A~ and ET~A/B~ receptor antagonists are variable (for reviews see [@B25]; [@B3]; [@B43]) with, as presently cited, lowered pressure in pig ([@B37], [@B39], [@B41], [@B38]; [@B22]; [@B14]; [@B62]) and in one human study ([@B32]), but not in other studies in human ([@B8]; [@B31]; [@B52]; [@B1], [@B2]), and neither in dog ([@B53]; [@B51]) and rat ([@B28]). The apparent limited role for ET-1 regulation of vascular tone under physiological conditions has been attributed in part to possible minimization of any potential ET-1 constriction by NO, which causes both vasodilation and inhibits ET-1 synthesis ([@B55]; [@B15]).

Moreover, even if ET-1 were to regulate arterial pressure, this effect would presumably be on a sustained rather than dynamic, i.e., moment-to-moment basis ([@B18]; [@B15]). This conclusion follows from the widely reported observation that the ET-1 constriction is highly resistant to reversal, as demonstrated following intravenous ET-1 bolus and ET-1 washout *ex vivo* ([@B60]; [@B10],[@B11]; [@B42]; [@B18]; [@B34], [@B35]; [@B15]).

In apparent contradiction to these general assessments, however, it appears that with exercise not only does ET-1 serve as a physiologic regulator of vascular tone but that the regulation is dynamic (**Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). This evidence is presently reviewed and underlying mechanisms surmised.

###### 

Effect of endothelin receptor antagonists on flow in non-primate mammals.

                                   Flow^1^               
  ---------------- ----- --------- --------- --- ------- --------
  **Coronary**     Dog   ET~A/B~   --        ↑   \-^2^   [@B51]
                   Pig   ET~A~     ↑         ↑   ↓       [@B37]
                         ET~A~     ↑         ↑   ↓^3^    [@B39]
                         ET~A/B~   ↑↑        ↑   ↓^4^    
                         ET~A~     ↑         ↑   ↓^3^    [@B40]
                         ET~A/B~   ↑         ↑   ↓^4^    
                         ET~A/B~   ↑         ↑   ↓       [@B41]
                         ET~A/B~   ↑         ↑   ↓^4^    [@B14]
                         ET~A/B~   ↑         ↑   ↓^4^    [@B61]
  **Lung**         Pig   ET~A~     --        ↑   --      [@B39]
                         ET~A/B~   --        ↑   ↑       
                         ET~A~     --        ↑   --      [@B22]
                         ET~A/B~   --        ↑   ↑       
                         ET~A/B~   --        ↑   ↑       [@B38]
                         ET~A/B~   --        ↑   ↑       [@B13]
                         ET~A/B~   --        ↑   ↑       [@B62]
                                                         
  **Skeletal**     Rat                                   [@B28]
  Plantaris              ET~A~     --        ↑   ↓       
                         ET~A/B~   --        ↑   ↓       
  Soleus                 ET~A~     --        ↑   ↓       
  Tibialis               ET~A~     --        ↑   ↓       
                         ET~A/B~   --        ↑   ↓       
  **Splanchnic**   Rat                                   
  Intestine              ET~A~     --        ↓   ↑       [@B28]
                         ET~A/B~   --        ↓   ↑       
                         ET~A~     --        ↓   ↑       
                         ET~A/B~   --        ↓   ↑       
  Spleen                 ET~A~     --        ↓   ↑       
                         ET~A/B~   --        ↓   ↑       
  Stomach                ET~A~     --        ↓   ↑       
                         ET~A/B~   --        ↓   ↑       
                                                         

1

Pressure in lungs,

2

Increased coronary sinus O

2

,

3

Waned with exercise intensity,

4

Obliterated with exercise intensity, ↑, ↓, -- = increase, decrease, no change.

###### 

Effect of endothelin receptor antagonists on resting and exercise-elevated flow in humans.

                                                           Flow          
  --------- -------- --------------------------- --------- ------ ------ --------------
  Forearm   20--43                               ET~A~     ↑↑     n.d.   [@B56]
                                                 ET~A/B~   ↑      n.d.   
            47                                   ET~A~     --     n.d.   [@B8]
                                                 ET~A/B~   --     n.d.   
            51                                   ET~A~     --     n.d.   [@B7]
            55       Hypercholesterolemia        ET~A~     ↑      n.d.   
                     Hypercholesterolemia        ET~A/B~   --     n.d.   
            18--30                               ET~A~     ↑      n.d.   [@B50]
            48                                   ET~A~     --     n.d.   [@B5]
            50       Type 2 diabetes             ET~A~     ↑      n.d.   
                     Type 2 diabetes             ET~A/B~   ↑      n.d.   
            54                                   ET~A/B~   ↑      ↑^2^   [@B31]
            54       Hypertension                ET~A/B~   ↑      ↑^2^   
            50                                   ET~A~     ↑      ↑      [@B33]
            49       Hypertension                ET~A~     ↑      ↑↑     
            48^3^                                ET~A~     --     n.d.   [@B6]
                     Overweight                  ET~A~     --     n.d.   
                     Obese                       ET~A~     --     n.d.   
            50^4^    Hypertension                ET~A~     --     n.d.   
                     Hypertension + Overweight   ET~A~     ↑      n.d.   
                     Hypertension + Obese        ET~A~     ↑↑     n.d.   
            55                                   ET~A~     --     n.d.   [@B49]
                                                 ET~A/B~   --     n.d.   
            53       Insulin resistance          ET~A~     ↑      n.d.   
                     Insulin resistance          ET~A/B~   --     n.d.   
            27                                   ET~A~     --     n.d.   [@B54]
            62                                   ET~A~     ↑      n.d.   
            27                                   ET~A/B~   --     n.d.   
            62                                   ET~A/B~   ↑      n.d.   
            55                                   ET~A~     --     n.d.   [@B57]
            56       Overweight                  ET~A~     ↑      n.d.   
            57       Obese                       ET~A~     ↑      n.d.   
            60                                   ET~A/B~   --     ↑^5^   [@B48]
            60       Type 2 diabetes             ET~A/B~   --     ↑^5^   
            54                                   ET~A~     --     n.d.   [@B17]
            56       Overweight/Obese            ET~A~     ↑      n.d.   
  Leg       33                                   ET~A~     --     n.d.   [@B32]
            45       Type 2 diabetes             ET~A~     ↑      n.d.   
            34       Obese                       ET~A~     ↑      n.d.   
            34                                   ET~A/B~   --     n.d.   [@B52]
            70                                   ET~A/B~   ↑      n.d.   
            24                                   ET~A~     --     ↑      [@B1], [@B2]
            70                                   ET~A~     ↑      ↑↑     
                                                                         

1

Mean or range,

2

Plethysmography-induced reactive hyperemia,

3

Mean for lean, overweight and obese,

4

Mean for hypertensive, hypertensive + overweight and hypertensive + obese,

5

Continuous but not incremental exercise ↑, ↓, --, n.d. = increase, decrease, no change, not determined.

ET Receptor Antagonist Effects on Exercise-Induced Changes in Blood Flow
========================================================================

The effect of ET~A~/ET~A/B~ receptor antagonists, particularly when administered systemically, on local flow should be interpreted in combination with changes in local metabolism when possible. Autoregulation will attempt to maintain blood flow constant and hence vascular diameter will vary when blood pressure changes in response to systemically administered vasodilators.

Heart
-----

Since systemic vasodilation is accompanied by changes in heart rate and blood pressure, the oxygen demand of the myocardium is likely to be altered. Optimal methodology for the assessment of vascular tone is by relating changes in myocardial oxygen supply to changes in myocardial oxygen demand. When this is not possible, changes in coronary blood flow and/or diameter of the large coronary vessels could potentially be used as an indicator of the vasoactive effects, particularly when ET~A~/ET~A/B~ receptor antagonists are infused intracoronarily.

### Rest

ET~A~/ET~A/B~ receptor antagonists increased coronary blood flow or dilated the coronary vasculature, depending on the species (**Table [1](#T1){ref-type="table"}**). In dog, although intracoronarily ([@B53]) and intravenously ([@B51]) infused ET~A~ and ET~A/B~ receptor antagonists did not increase coronary flow (**Table [1](#T1){ref-type="table"}**), infusion dilated the external coronary circumflex artery ([@B53]) and increased coronary sinus O~2~ saturation, consistent with coronary dilation ([@B51]). ET~B~ receptor antagonism and NO synthase inhibition did not alter the diameter of the external coronary circumflex artery, although coronary flow decreased ([@B53]).

In pig, intrapulmonary artery infused ET~A~ and ET~A/B~ receptor antagonist increased flow/dilated the coronary vascular bed ([@B37], [@B39], [@B40], [@B41]; [@B14]; [@B61]; **Table [1](#T1){ref-type="table"}**). The magnitude of increase was slightly, but significantly greater with ET~A~ receptor antagonism as compared to ET~A/B~ receptor antagonism, suggesting the presence of underlying endothelial ET~B~ receptor vasodilation ([@B39]; **Table [1](#T1){ref-type="table"}**). Along these lines, although NO synthase and cyclooxygenase inhibition did not enhance ET~A/B~ receptor antagonist increased flow, it was speculated that ischemia due to NO synthase and cyclooxygenase inhibition resulted in release of a vasodilator, e.g., adenosine, which masked the decreased flow ([@B41]). Indeed, the possibility that ET~A/B~ receptor antagonist inhibited NO release is supported by the lack of additivity of the elevated flows by ET~A/B~ receptor antagonist and an inhibitor of phosphodiesterase-5; the latter preventing the breakdown of the NO-mediator of vasodilation, cyclic GMP ([@B61]). Thus, even at rest, the capacity of the endothelium to synthesize/release ET-1 is reduced by NO. It should be noted, however, that an increase in ET-1 plasma levels in the coronary vascular bed (arteriovenous difference) was not detected following NO synthase inhibition ([@B41]).

While an explanation is not clear with respect to the enhancement and lack of effect of ET~A~/ET~A/B~ receptor antagonism on resting flow in the coronary vasculature of the pig ([@B37], [@B39], [@B40], [@B41]) and dog ([@B53]; [@B51]), respectively, one possibility is differences in the regulation of the coronary vasculature in these species ([@B41], [@B36]). In this regard, in dog coronary vasculature, cyclooxygenase and NO synthase inhibition was without effect and caused minimal constriction, respectively (as cited in [@B41], [@B36]). In contrast, in the coronary vasculature of the pig and, notably, in human, cyclooxygenase and NO synthase inhibition caused vasoconstriction ([@B41], [@B36]).

### Exercise

ET~A~/ET~A/B~ receptor antagonists increased coronary blood flow and/or dilated the coronary vasculature, depending on the species (**Table [1](#T1){ref-type="table"}**). In dog, intravenous infused ET~A/B~ receptor antagonist increased coronary sinus O~2~ saturation ([@B51]), consistent with coronary dilation, although elevated coronary flow was not detected ([@B51]; **Table [1](#T1){ref-type="table"}**). With ventricular pacing, which did not increase coronary flow, ET~A~ and ET~A/B~ receptor antagonists increased the diameter of the external coronary circumflex artery to a similar magnitude as observed with these antagonists at rest ([@B53]). NO synthase inhibitor did not alter the ET~A~ and ET~A/B~ receptor antagonist-increased diameter of the external coronary circumflex artery with ventricular pacing ([@B53]).

In pig, intrapulmonary artery infused ET~A~ and ET~A/B~ receptor antagonist increased coronary dilation, with the magnitude of increase slightly but significantly greater with ET~A~ receptor antagonist at all levels of exercise intensity ([@B37], [@B39], [@B40], [@B41]; [@B14]; [@B61]; **Table [1](#T1){ref-type="table"}**). With increasing exercise intensity, however, the additional vasodilator effect due to ET~A~ and ET~A/B~ receptor antagonism waned and was obliterated, respectively ([@B39], [@B40]; **Table [1](#T1){ref-type="table"}**). As with rest, the magnitude of increase was slightly but significantly greater with ET~A~ receptor antagonism as compared to ET~A/B~ receptor antagonism ([@B39]; **Table [1](#T1){ref-type="table"}**). Contrary to the coronary ET~A~ receptor vasoconstrictor influence that waned with increasing exercise intensity, the ET~B~ receptor mediation vasodilation was similar at all exercise intensities ([@B39], [@B41]).

Despite the underlying ET~B~ receptor mediated vasodilation, neither NO synthase inhibition nor cyclooxygenase inhibition enhanced the vasodilation by ET~A~ and ET~A/B~ receptor antagonism ([@B41]). However, in the presence of inhibitors of NO synthase and/or cyclooxygenase, the vasodilator effect of ET~A/B~ receptor blockade was sustained with increasing exercise intensity, with combined inhibition eliciting additive effects ([@B41]). Moreover, in the presence of NO synthase and cyclooxygenase inhibitors there was a positive correlation between ET~A/B~ receptor antagonist-increased flow and exercise intensity ([@B41]; [@B14]). Thus, increased exercise intensity resulted in greater NO- and prostaglandin-mediated suppression of ET-1-mediated coronary vasoconstriction ([@B41]).

Several findings suggest that the ability of NO synthase inhibitor to prevent the ET~A/B~ receptor antagonist obliteration of increased flow is due to reversal of NO inhibition of ET-1 synthesis. Increasing exercise intensity caused a dose-dependent decrease in ET-1 synthesis in the coronary vasculature, but not in the systemic circulation, as assessed by the conversion of big ET-1 to ET-1 ([@B12]). NO synthase inhibition also increased ET-1 plasma levels in the coronary vasculature (coronary arteriovenous difference; [@B41]). Decreased ET-1 synthesis with exercise is also consistent with lowered pre-pro ET-1 mRNA expression in the aorta following 30 min (shortest duration studied) in the rat ([@B27]). Further, the NO-mediated vasodilation was not due to decreased ET-1 constriction because contractile sensitivity to infused exogenous ET-1 remained unaltered with exercise ([@B12]). Also, phosphodiesterase-5 inhibition and 8-Br-cGMP did not decrease ET-1 constriction, whereas the endothelium-dependent constriction to big ET-1 was decreased in isolated coronary resistance vessels ([@B61]). These findings are consistent with NO synthase inhibitor-increased big ET-1, but not ET-1, constriction of isolated rat mesenteric artery ([@B4]).

### Conclusion and Speculation

The ability of ET~A~ and ET~A/B~ receptor antagonists to increase coronary flow at rest and with exercise demonstrates that ET-1 dynamically, i.e., on a moment-to-moment basis, limits coronary flow under both conditions (**Table [1](#T1){ref-type="table"}**). Moreover, the coronary endothelium has a greater capacity to release ET-1 with increased exercise intensity, an effect that is limited by NO inhibition of ET-1 synthesis. Thus, the dynamic regulation of flow by ET-1 is modulated by a dynamic balance between increased ET-1 synthesis and subsequent ET-1 release, and increased inhibition of ET-1 synthesis by enhanced NO.

It is of interest to consider that a major influence of the balance between NO and ET-1 is pulsatile shear stress. In this regard, the coronary bed is exposed to relatively high levels of shear stress even at rest ([@B46]). Indeed, the magnitude of basal flow in the coronary vascular bed is similar to flow in exercised skeletal muscle ([@B24]). With increased exercise intensity, shear stress increases, resulting in further NO release and lowering ET-1 synthesis ([@B39], [@B41]; [@B44]). Furthermore, it should be considered that along with a major effect of shear stress to increase NO release, endothelial ET~B~ receptor activation provides a relatively smaller component of NO, in particular at higher levels of exercise intensity.

Splanchnic: Intestine, Kidney, Spleen, and Stomach
--------------------------------------------------

### Rest

Intra-aortic infused ET~A~ and ET~A/B~ receptor antagonists did not alter resting flow in intestine, kidney, spleen, and stomach ([@B28]; **Table [1](#T1){ref-type="table"}**).

### Exercise

Exercise decreased flow in intestine, kidney, spleen, and stomach ([@B28]; **Table [1](#T1){ref-type="table"}**). The amount of exercise-lowered flow was reduced by ET~A~ and ET~A/B~ receptor antagonism ([@B28]; **Table [1](#T1){ref-type="table"}**). Similar magnitudes of attenuation of the decreased flow with exercise were achieved with ET~A~ and ET~A/B~ receptor antagonists ([@B28]; **Table [1](#T1){ref-type="table"}**).

### Conclusion and Speculation

Consistent with ET-1 as a dynamic regulator of vascular tone, is the ET~A~ and ET~A/B~ receptor antagonist reduction of exercise-induced decreased flow to intestine, kidney, spleen, and stomach ([@B28]; **Table [1](#T1){ref-type="table"}**). Thus, ET-1 appears to regulate exercise-mediated redistribution of blood flow away from the splanchnic circulation to other organs, e.g., skeletal muscle (see below; [@B28]). The similar magnitude of ET~A~ and ET~A/B~ receptor antagonist-mediated reduction of exercise-induced decreased flow ([@B28]; **Table [1](#T1){ref-type="table"}**) suggests that ET-1 activation of endothelial ET~B~ receptors does not modulate this reduction.

The lack of effect of ET~A~ and ET~A/B~ receptor antagonism on resting flow in splanchnic organs is consistent with the lesser magnitude of sheer stress to which these organs are subjected at rest as compared to the coronary vascular bed, in which ET~A~ and ET~A/B~ receptor antagonism increased resting flow (see section "Heart"; **Table [1](#T1){ref-type="table"}**). That is, ET-1 release is increased with modest elevations in shear stress and the level of NO release may be insufficient to counter, through inhibition of ET-1 synthesis, the increased ET-1 release ([@B44]).

Skeletal Muscle
---------------

### Rest

ET~A~ and ET~A/B~ receptor antagonism were largely without effect on resting skeletal muscle blood flow in healthy human volunteers, as demonstrated in the forearm and leg with intra-brachial artery ([@B8], [@B7], [@B5], [@B6]; [@B49]; [@B54]; [@B57]; [@B48]; [@B17]) and intra-femoral artery infused antagonist, respectively ([@B52]; [@B1], [@B2]; **Table [2](#T2){ref-type="table"}**). In contrast, other studies demonstrated increased forearm flow with intra-brachial ET~A~ and ET~A/B~ receptor antagonist infusion ([@B56]; [@B50]; [@B31]; [@B33]; **Table [2](#T2){ref-type="table"}**).

An explanation for the contrasting effects of ET~A~ and ET~A/B~ receptor antagonists on resting flow does not appear to be the age of the volunteers. Specifically, while ET~A~/ET~A/B~ receptor antagonist-increased flow in forearm and leg was restricted to aged humans ([@B54]; [@B1], [@B2]; **Table [2](#T2){ref-type="table"}**), others demonstrated increased forearm flow with ET~A~/ET~A/B~ receptor antagonism in relatively younger volunteers ([@B56]; [@B50]). Another possibility is that undetected endothelial dysregulation is present in otherwise healthy volunteers. Along these lines, ET~A~/ET~A/B~ receptor antagonism increased forearm resting flow in volunteers with hypercholesterolemia, insulin resistance, type 2 diabetes, excessive weight, and combined excessive weight and hypertension, but not in normal control volunteers ([@B7], [@B5], [@B6]; [@B32]; [@B49]; [@B57]; [@B17]; **Table [2](#T2){ref-type="table"}**). Possibly in general support of this explanation is that intra-aorta infused ET~A~ and ET~A/B~ receptor antagonists did not lower blood flow in plantaris, soleus, and tibialis muscle of rats 10 weeks of age ([@B28]; **Table [1](#T1){ref-type="table"}**). It should also be noted, though, that other studies were unable to demonstrate increased forearm flow with ET~A~/ET~A/B~ receptor antagonism in volunteers with excessive weight and type 2 diabetes ([@B6]; [@B48]; **Table [2](#T2){ref-type="table"}**).

In any case, the increased forearm flow at rest elicited by ET~A~ receptor antagonism was attributed to underlying endothelial ET~B~ receptor-mediated dilation because NO synthase inhibition and ET~B~ receptor antagonism reduced the ET~A~ receptor antagonist-induced increase in flow, and ET~B~ receptor antagonism alone decreased flow ([@B56]; **Table [2](#T2){ref-type="table"}**). Along the general line of the involvement of NO-mitigation of the decreased flow due to ET-1, in volunteers with hypercholesterolemia and insulin resistance, ET~A~, but not ET~A/B~ receptor antagonism, increased flow ([@B7]; [@B49]). Although, in volunteers with type 2 diabetes and aged volunteers, ET~A~ and ET~A/B~ receptor antagonism elicited similar increases in flow ([@B5]; [@B54]). Thus, NO-mitigation of decreased flow due to ET-1 appears to depend on the disease state.

### Exercise

In healthy human volunteers, exercise caused a similar magnitude of ET~A~ receptor antagonist-induced elevation of forearm blood flow as at rest ([@B33]; **Table [2](#T2){ref-type="table"}**). In the leg, in contrast to the lack of ET~A~ receptor antagonist-increased flow at rest, ET~A~ receptor antagonism increased flow with exercise ([@B1], [@B2]). Hypertension, type 2 diabetes, and age were associated with ET~A~/ET~A/B~ receptor antagonist increased flow in forearm and leg with exercise and were even enhanced as compared to the ET~A~ receptor antagonism increased flow observed at rest ([@B33]; [@B1], [@B2]; [@B48]; **Table [2](#T2){ref-type="table"}**). Although plethysmography-induced reactive hyperemia was increased by ET~A/B~ receptor antagonism to similar magnitudes in healthy and hypertensive volunteers ([@B31]; **Table [2](#T2){ref-type="table"}**), it is not clear whether plethysmography-induced reactive hyperemia mimics the effects exercise.

In rat, intra-aortic infusion of ET~A~ and ET~A/B~ receptor antagonists actually resulted in a reduction in flow in tibialis and plantaris muscle with exercise as compared to rest ([@B28]; **Table [1](#T1){ref-type="table"}**). It should be considered, however, that the reduced flow was a direct effect of the decreased arterial pressure due to intra-aortic infusion of ET~A~ and ET~A/B~ receptor antagonist ([@B28]).

The involvement of ET-1 production in exercise is equivocal. With one-legged exercise, ET-1 production increased in the non-exercising leg, whereas it was not changed in the exercising leg ([@B29]). Conversely, ET-1 production was increased during knee exercise-extensor exercise in the exercising leg ([@B1]). An additional complexity is that NO formation, which is increased with exercise as demonstrated through NO synthase inhibition of dilation of the brachial artery with handgrip ([@B59]), would be anticipated to decrease ET-1 production increased by pulsatile shear stress ([@B44]).

Changes in ET-1 contractile sensitivity of the skeletal muscle vasculature also occur with exercise. Indeed, the vasoconstrictor influence of infused ET-1 was progressively reduced with incremental exercise intensity in the leg ([@B58]).

### Conclusion and Speculation

These findings (**Table [2](#T2){ref-type="table"}**) are consistent with ET-1 as a dynamic regulator of vascular tone in the skeletal muscle with exercise. The changes in production and sensitivity together result in an altered contribution of ET-1 to skeletal muscle blood flow during exercise. The variable effects of ET-1 involvement at rest may point to different degrees of underlying endothelial dysregulation. Indeed, pathophysiologies associated with endothelial dysregulation also demonstrate dynamic ET-1 dependency of flow with rest and exercise.

Lung
----

### Rest

In lying and standing young pig (2--3 months), an intra-pulmonary artery infused ET~A~ receptor antagonist was without effect on pulmonary arterial pressure ([@B39], [@B38]; [@B22]; [@B13]; [@B62]; **Table [1](#T1){ref-type="table"}**). While ET~A/B~ receptor antagonism also did not lower pulmonary arterial pressure in lying pig, in a number of studies pressure was lowered in standing pig ([@B39], [@B38]; [@B22]; [@B13]; [@B62]; **Table [1](#T1){ref-type="table"}**). The lack of role of ET-1 in basal tone in lying pig may be due to ongoing NO inhibition of ET-1 synthesis because NO synthase inhibition increased pulmonary vascular resistance and an ET~A/B~ receptor antagonist prevented the increase ([@B38]). Further, in standing pig (not investigated in lying pig), pulmonary arterial pressure was reduced by phosphodiesterase-5 inhibition and ET~A/B~ receptor blockade failed to further reduce pressure in the presence of phosphodiesterase-5 inhibition ([@B62]).

### Exercise

ET~A/B~, but not ET~A~ receptor antagonism, prevented exercise-induced increased pulmonary arterial pressure ([@B39]; **Table [1](#T1){ref-type="table"}**). Thus, it was concluded that the ET-1-elevated tone during exercise was mediated by (smooth muscle) ET~B~ receptors ([@B39]). Indeed, ET~B~ receptor-mediated, ET-1-elevated tone of the pulmonary vasculature during exercise is consistent with ET~B~ receptor mediation of constriction of pulmonary resistance vessels ([@B26]).

Also, ongoing NO release inhibits the ET-1 increase in resistance as demonstrated by enhancement of the ET~A/B~ receptor antagonism-induced decrease in pulmonary arterial pressure with NO synthase inhibition ([@B38]). Consistent with an underlying role for NO in inhibition of ET-1 release is lack of further increase in pulmonary arterial pressure by ET~A/B~ receptor following inhibition of phosphodiesterase-5 ([@B62]). Furthermore, the effect of phosphodiesterase-5 inhibition to lower pulmonary arterial pressure was due to decreased ET-1 synthesis, as demonstrated by inhibition of big ET-1 constriction in isolated pulmonary resistance vessels ([@B62]).

### Conclusion and Speculation

Consistent with ET-1 as a dynamic regulator of vascular tone is the ET~A/B~ receptor antagonist reduction of exercise-induced decreased pulmonary arterial pressure by ET~A/B~ receptor antagonism (**Table [1](#T1){ref-type="table"}**). The release of ET-1 in response to exercise is consistent with the ability of moderate levels of pulsatile shear stress to increase ET-1 release ([@B44]).

The lack of effect of ET~A/B~ receptor antagonism on resting pressure (lying pig) presumably reflects in part lower ET-1 release due to lesser pulsatile shear stress, i.e., similar to that observed in splanchnic organs (see section "Splanchnic: Intestine, Kidney, Spleen, and Stomach"). Another factor involved in the lack of effect of ET~A/B~ receptor antagonism at rest is NO inhibition of ET-1 synthesis. While the relative contribution of NO released in response to endothelial ET~B~ receptor activation and shear stress is not clear, it may be reasonable to consider that the relative amount of NO release by endothelial ET~B~ receptor activation is considerably greater than in the coronary vasculature (see section "Heart").

Overall Conclusion and Speculation
==================================

These studies demonstrate that ET-1 dynamically regulates vascular tone with exercise. The resultant changes in blood flow redistribute flow away from metabolically less demanding organs/tissue in favor of those with greater demands ([@B28]). By extension, ET-1 alterations of vascular tone continuously diverts blood flow to organs in response to even subtle demands, i.e., beyond what is recognized as "exercise."

Major factors which influence the ET-1-dependent regulation of vascular tone are pulsatile shear stress and NO. This influence occurs through changes in ET-1 synthesis, rather than direct effects of shear stress and NO on ET-1 contractile potency. Thus, under conditions of moderate shear stress, which increases ET-1 release, NO release is also increased, thereby limiting the release of ET-1 in response to shear stress ([@B44]). NO derived from ET-1-induced, endothelial ET~B~ receptor activation also acts to limit ET-1 synthesis, although in organs exposed to higher levels of shear stress, e.g., heart, the relative amount of ET~B~ receptor-derived NO as compared to shear stress-derived NO may be minimal.

In possible conflict with ET-1 serving as a dynamic regulator of vascular tone is the resistance of ET-1 constriction to reversal (see section "Introduction"). While an explanation for this apparent conflict is not entirely clear, it should be noted that the resistance of ET-1 to reversal is based upon findings with exogenous ET-1. Thus, the effects of exogenous ET-1 may not entirely mimic those due to endogenous ET-1, and notably with respect to reversibility of the constriction. At least along these general lines, despite the numerous findings of functional (constriction) cross-talk between ET~A~ and ET~B~ receptors in the normal (physiologic) vasculature as uncovered with exogenous ET-1 ([@B45]), demonstrations of cross-talk with endogenously released ET-1, at least under physiologic conditions, remain to be established (to our knowledge).

Possible lack of mimicry of endogenously released ET-1 by exogenous ET-1 could also involve conditions under which endogenous ET-1 elicits constriction. In this regard, calcitonin gene-related peptide (CGRP) selectively reversed constriction and prevented re-constriction of a number of isolated vessels (but not all vessels examined) challenged with exogenous ET-1 and terminated the elevated arterial pressure to intravenous bolus ET-1 injection ([@B34], [@B35]). The CGRP inhibition of ET-1vasoconstriction was attributed to dissociation of the quasi-irreversible ET-1-ET~A~ complex ([@B21]; [@B34]). It would be of interest to investigate whether CGRP selectively prevented/reversed the ET-1-dependent component of exercise-altered flow and CGRP receptor antagonists prevented the reversal of these changes in flow.

Finally, an additional speculative explanation for the apparent contradiction that ET-1 dynamically regulates vascular tone while the constriction to (exogenous) ET-1 is resistant to reversal relates to the dependency of the maintained ET-1 constriction upon externalization of ET~A~ receptors ([@B30]). That is, the ET-1-ET~A~ receptor complex is rapidly internalized and the ET~A~ receptor recycled to the cell membrane, whereupon the receptor is again subject to ET-1 binding ([@B30]). The magnitude of ET-1 constriction at any particular point in time would, therefore, reflect both reversal due to internalization of the ET-1-ET~A~ receptor complex and constriction by newly released ET-1 binding to both previously unbound and recycled ET~A~ receptors. Thus, reversible ET-1-mediated constriction could be achieved if the amount of ET-1 release were actually relatively low, although it has also been speculated that the (decreasing) fraction of internalized ET-1-ET~A~ receptor complex is still coupled to signaling ([@B47]; [@B9]).

It is widely recognized that numerous vascular pathophysiologies are associated with increased ET-1-dependent tone and, furthermore, that this tone reflects an imbalance between NO and ET-1 (see section "Introduction"). Indeed, this imbalance also represents changes in the dynamic regulation of vascular tone by ET-1, with the balance favoring ET-1 release (see section "Introduction"). In this regard, ET-1 limitation of flow with exercise is enhanced in skeletal muscle with hypertension, hypercholesterolemia, type 2 diabetes and aging ([@B20]; **Table [2](#T2){ref-type="table"}**) and in the lung in pulmonary hypertension secondary to myocardial infarction ([@B22]; [@B38]), while the ET-1 limitation of flow is reduced in heart with myocardial infarction ([@B40]; [@B14]). While these ET-1-dependent changes in flow with exercise reflect the differential influence of numerous vasoactive factors, an understanding of the detailed mechanism whereby ET-1 release is altered with exercise will provide further insight into these vascular lesions.
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